Neurodegenerative diseases, encompassing Alzheimer's Disease (AD), Parkinson's Disease (PD), Huntington's Disease (HD), Amyotrophic Lateral Sclerosis (ALS), etc., areprogressive, fatal, and complex disorders. These diseases are characterized by insidious onset, long disease duration, and a scarcity of effective treatment options. They typicallymanifest distinct symptomatic features in middle-aged and elderly populations, often at anadvanced stage of the disease. Given the irreversible nature of neural damage, current treatment approaches can only minimally slow down the disease progression. Consequently, there is an urgent need for accurate, non-invasive, and affordable early diagnostic andscreening methods.
Accurate early diagnosis and screening can assist potential patients in proactivelymodifying their lifestyles and adhering to medication regimens, thereby reducingtheincidence rate, delaying the onset of the disease, and mitigating its progression, ultimatelyenhancing the quality of life.